{"id":43700,"date":"2025-10-17T15:58:26","date_gmt":"2025-10-17T07:58:26","guid":{"rendered":"https:\/\/flcube.com\/?p=43700"},"modified":"2025-10-17T15:58:27","modified_gmt":"2025-10-17T07:58:27","slug":"kexing-biopharm-easton-biopharma-sign-exclusive-overseas-licensing-deal-for-apalutamide","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43700","title":{"rendered":"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide"},"content":{"rendered":"\n<p><strong>Kexing Biopharm<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688136:SHA\">SHA: 688136<\/a>) today announced a strategic cooperation agreement with <strong>Chengdu Easton Biopharmaceuticals Co., Ltd.<\/strong> The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>License Scope<\/strong><\/td><td>Exclusive overseas commercialization of Easton\u2019s apalutamide tablets in 10+ countries<\/td><\/tr><tr><td><strong>Target Markets<\/strong><\/td><td>Southeast Asia, Middle East, Latin America<\/td><\/tr><tr><td><strong>Therapeutic Indication<\/strong><\/td><td>Metastatic hormone\u2011sensitive prostate cancer (mHSPC) &amp; non\u2011metastatic castration\u2011resistant prostate cancer (NM\u2011CRPC)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>\u201cDrug Registration Certificate\u201d issued by China\u2019s NMPA (May\u202f2025)<\/td><\/tr><tr><td><strong>Strategic Fit<\/strong><\/td><td>Second high\u2011end prostate\u2011cancer asset added to Kexing\u2019s portfolio after Enzalutamide<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-this-matters\">Why This Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid Market Penetration<\/strong> \u2013 Kexing\u2019s existing global sales network spans ~70 countries, enabling swift rollout of apalutamide in emerging markets.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 The agreement follows Kexing\u2019s in\u2011licensing of Qingfeng\u2019s Enzalutamide capsules, reinforcing its focus on premium prostate\u2011cancer therapies.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong> \u2013 Easton\u2019s product has already secured NMPA approval, positioning it for expedited entry into new jurisdictions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-context\">Company Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Kexing Biopharm<\/strong> is a Shanghai\u2011listed biopharmaceutical firm with a robust pipeline in oncology. It has a track record of securing approvals for multiple high\u2011profile drugs across diverse territories.<\/li>\n\n\n\n<li><strong>Easton Biopharma<\/strong> specializes in generics of advanced oncology agents. Its apalutamide tablets are a second\u2011generation, non\u2011steroidal androgen\u2011receptor inhibitor, offering a valuable option for patients with advanced prostate cancer.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43702,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,557,3625,1229],"class_list":["post-43700","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-easton-pharmaceutical","tag-kexing-biopharm","tag-sha-688136"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43700\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide\" \/>\n<meta property=\"og:description\" content=\"Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43700\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T07:58:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T07:58:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide\",\"datePublished\":\"2025-10-17T07:58:26+00:00\",\"dateModified\":\"2025-10-17T07:58:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700\"},\"wordCount\":283,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1710.webp\",\"keywords\":[\"Cancer\",\"Easton Pharmaceutical\",\"Kexing Biopharm\",\"SHA: 688136\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43700#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43700\",\"name\":\"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1710.webp\",\"datePublished\":\"2025-10-17T07:58:26+00:00\",\"dateModified\":\"2025-10-17T07:58:27+00:00\",\"description\":\"Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43700\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1710.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1710.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43700#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide - Insight, China&#039;s Pharmaceutical Industry","description":"Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43700","og_locale":"en_US","og_type":"article","og_title":"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide","og_description":"Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.","og_url":"https:\/\/flcube.com\/?p=43700","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-17T07:58:26+00:00","article_modified_time":"2025-10-17T07:58:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43700#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43700"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide","datePublished":"2025-10-17T07:58:26+00:00","dateModified":"2025-10-17T07:58:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43700"},"wordCount":283,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43700#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp","keywords":["Cancer","Easton Pharmaceutical","Kexing Biopharm","SHA: 688136"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43700#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43700","url":"https:\/\/flcube.com\/?p=43700","name":"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43700#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43700#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp","datePublished":"2025-10-17T07:58:26+00:00","dateModified":"2025-10-17T07:58:27+00:00","description":"Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton\u2019s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high\u2011growth markets across Southeast Asia, the Middle East and Latin America.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43700#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43700"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43700#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp","width":1080,"height":608,"caption":"Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43700#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kexing Biopharm &amp; Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1710.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43700"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43700\/revisions"}],"predecessor-version":[{"id":43703,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43700\/revisions\/43703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43702"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}